Skip to content
Screener

AtriCure ATRC Q2 2026 earnings

Reported July 23, 2026 · After market close

Revenue$153.6MBeat by $1.8M
EPS$0.18Beat by $0.18
Revenue estimate$151.8M
EPS estimate-$0.00
“Our innovative technologies continue to prove their value, with strong growth in pain management bolstering our leading cardiac surgery portfolio. Meanwhile, we are rapidly advancing our BoxX-NoAF and LeAAPS clinical trials towards data readouts that we believe will inform and drive the next era of cardiac surgery patient care and growth for AtriCure. We remain confident in our ability to create lasting value for patients and shareholders.”
Michael Carrel

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$151.2M
EPS estimate$0.01

Financials

Q2 2026

Income statement

See full
Revenue$153.6M+12.8%
Gross profit$118.6M+16.9%
Operating income$9.7M+256%
Net income$9.0M+245%
EPS (diluted)$0.18+238%

Balance sheet

See full
Cash & equivalents$167.8M+42.4%
Total debt$75.5M-3.8%
Total equity$516.4M+11.2%
Total assets$676.6M+11.1%

Cash flow

See full
Operating cash flow$22.2M+2.7%
CapEx$3.8M+41.5%
Free cash flow$18.4M-2.8%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$2.91B+67.0%
Enterprise value$2.81B+65.5%
P/E1,115.3×—
P/S5.1×+1.6×

Profitability

See full
Gross margin76.3%+1.6pp
FCF margin9.3%—

Returns & leverage

See full
Debt / equity0.1×0.0×
Current ratio4.2×+0.3×

Segments

By geography

See full
Total International$28.0M+9.6%
Europe$17.2M+6.7%
Asia Pacific$8.6M+15.4%
Other International$2.2M+12.1%

By product

See full
Appendage management$64.0M+14.4%
Open ablation$52.1M+11.3%
Pain management$29.4M+26.9%
Minimally invasive ablation$8.1M-21.2%

FAQ

When did AtriCure report Q2 2026 earnings?
AtriCure (ATRC) reported Q2 2026 earnings on July 23, 2026 after market close.
What were AtriCure's Q2 2026 revenue and EPS?
AtriCure reported revenue of $153.6M and eps of $0.18 for Q2 2026.
Did AtriCure beat estimates in Q2 2026?
Revenue beat the consensus estimate of $151.8M by $1.8M. EPS beat the consensus estimate of $-0.00 by $0.18.
How did AtriCure's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 12.8% from $136.1M a year earlier.
Where can I find AtriCure's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001323885-26-000032) and the 10-Q periodic report (0001323885-26-000035) directly on SEC EDGAR. The filing index links above go to sec.gov.